
|Articles|June 29, 2013
Mechanism of Action: Herceptin (Trastuzumab)
The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
Advertisement
Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Herceptin is approved for the treatment of early-stage breast cancer that isHumanEpidermal growth factorReceptor2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
3
Epcoritamab Monotherapy Yields Positive Results in Phase 3 R/R DLBCL Trial
4
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
5














































